Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menitorix immunogenicity and safety study in UK laboratory workers
2006-004302-74Phase 4Completed
- Sponsor
- Health Protection Agency
- Start
- Aug 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Hib-MenC-TT in Haemophilus influenzae type b disease (Hib) and meningococcal disease, sponsored by Health Protection Agency. Primary endpoints: Proportion achieving protective meningococcal serogroup C serum bactericidal antibody titer, Proportion achieving protective Hib IgG concentration and 1 more. Started Aug 2011; status: completed.
02
Drugs
Hib-MenC-TT
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal disease
Beyond the preview
Go deeper on 2006-004302-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004302-74.